2024-11-07 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

This report provides a comprehensive analysis of Thermo Fisher Scientific Inc. (TMO) stock, considering its performance, financial data, recent news, and analyst opinions.

**1. Performance and Comparison with S&P 500 (VOO):**

Thermo Fisher Scientific Inc. (TMO) is a leading provider of scientific instruments, reagents, consumables, software, and services used in research, diagnostics, and pharmaceutical development.

**Cumulative Return:**

* **TMO:** 219.42%
* **VOO:** 134.06%

**Outperformance:** TMO has significantly outperformed the S&P 500 (VOO) with a cumulative return of 85.36% higher. 

**Relative Outperformance:**  TMO's relative outperformance ranks at the 39.85th percentile based on historical data, meaning its current outperformance sits within the top 40% of its historical range.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|-------|
| 2015-2017 | 48.2% | 14.4% | 18.0% | 1.1 |
| 2016-2018 | 61.3% | 17.3% | 36.6% | 1.1 |
| 2017-2019 | 126.1% | 17.3% | 83.0% | 1.1 |
| 2018-2020 | 141.4% | 24.6% | 102.3% | 0.8 |
| 2019-2021 | 204.1% | 24.6% | 114.3% | 0.8 |
| 2020-2022 | 68.7% | 26.2% | 51.0% | 0.8 |
| 2021-2023 | 12.5% | 33.2% | -16.3% | 0.9 |
| 2022-2024 | -13.1% | 31.0% | -33.7% | 0.9 |

The table shows that TMO consistently generated higher returns (CAGR) than the market (S&P 500) with a significant alpha in most periods. Its beta remained around 1, indicating a similar volatility to the market. However, there was a slight dip in performance and alpha in recent years (2022-2024), which might reflect the market downturn.

**2. Recent Price Movement:**

* **Last Market Price:** 559.67
* **5-day Moving Average:** 554.22
* **20-day Moving Average:** 576.41
* **60-day Moving Average:** 598.8

The stock price is currently trading below its 5-day, 20-day, and 60-day moving averages, suggesting a potential downward trend in the short-term.

**3. Technical Indicators:**

* **RSI:** 33.03 - This indicates that the stock is currently in oversold territory, suggesting a potential bounce back.
* **PPO:** -0.25 - This indicates a weak short-term momentum and potential bearish trend.
* **Delta_Previous_Relative_Divergence:** -9.65 (-) - This indicates a short-term downtrend in relative outperformance.
* **Expected Return:** 46.53% - This indicates a potential long-term (2 years or more) outperformance compared to the S&P 500, assuming consistent growth and market conditions. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2024-11-01 | 4.44 | 10.57 B$ |

TMO has consistently exceeded revenue expectations, demonstrating its strong market position. However, the most recent earnings (2024-11-01) were slightly below analysts' estimates.  Despite this slight miss, the company remains optimistic about future growth, driven by its diversified product portfolio and strong demand in key markets. 

**5. Financial Data:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.60B | 40.84% |
| 2024-06-30 | $10.54B | 41.24% |
| 2024-03-31 | $10.35B | 40.65% |
| 2023-12-31 | $10.89B | 40.35% |
| 2023-09-30 | $10.57B | 40.82% |

The company has shown consistent revenue growth and profitability with high profit margins. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $48.99B | 3.33% |
| 2024-06-30 | $47.43B | 3.26% |
| 2024-03-31 | $45.52B | 2.92% |
| 2023-12-31 | $46.73B | 3.49% |
| 2023-09-30 | $45.33B | 3.78% |

The company demonstrates strong financial health with stable equity and steady return on equity.

**6. News and Recent Issues:**

* The latest earnings release on November 1st, 2024, saw a slight miss in EPS expectations but was generally received positively.
* The company's recent expansion into new markets, such as diagnostics and pharmaceutical development, is driving growth and investor interest.

**Recent Market Outlook for TMO:**

According to FINBOLD, TMO is considered a strong buy by analysts, with a median price target of $600. The company's strong fundamentals, consistent growth, and market leadership position are seen as driving factors for future performance.

**7. Analyst Opinions and Performance Highlights:**

* Most analysts are bullish on TMO's long-term prospects, citing its strong market share, consistent profitability, and strategic growth initiatives.
* **Shaacknews:**  Highlighted the company's commitment to innovation and its recent acquisitions that are expanding its portfolio and market reach.

**8. Summary and Conclusion:**

TMO has shown significant outperformance compared to the S&P 500, with a strong history of exceeding earnings expectations. The company's recent financial performance and long-term growth potential continue to attract investors, as evidenced by analyst recommendations and market outlook.  The stock is currently in oversold territory, suggesting a potential rebound.  Investors considering a long-term investment in TMO should be aware of the recent short-term downtrend but recognize the company's strong fundamentals and future growth prospects.

**9. Disclaimer:**

This report is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on independent research and consultation with a qualified financial advisor. 
